Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

23.15
+0.08000.35%
Post-market: 22.97-0.1800-0.78%19:51 EST
Volume:2.35M
Turnover:53.98M
Market Cap:2.35B
PE:-5.24
High:23.40
Open:23.05
Low:22.17
Close:23.07
52wk High:35.25
52wk Low:13.53
Shares:101.47M
Float Shares:89.94M
Volume Ratio:0.86
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4166
EPS(LYR):-4.5769
ROE:-47.19%
ROA:-23.48%
PB:2.43
PE(LYR):-5.06

Loading ...

RBC Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
Yesterday

Beam Therapeutics (BEAM) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Nov 05

CRSP, BEAM, ROKU, SOFI: Cathie Wood Pours $17 Million into Biotech Stocks, Trims Tech Favorites

TIPRANKS
·
Nov 05

Cathie Wood’s ARK Investment buys 291K shares of Beam Therapeutics today

TIPRANKS
·
Nov 05

Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses

Reuters
·
Nov 04

Beam Therapeutics reports third quarter cash position of $1.1 billion

Reuters
·
Nov 04

Beam Therapeutics Q3 License and Collaboration Revenue USD 9.698 Million

THOMSON REUTERS
·
Nov 04

Beam Therapeutics Inc - Q3 EPS $-1.10

THOMSON REUTERS
·
Nov 04

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

THOMSON REUTERS
·
Nov 04

Beam Therapeutics to Present Updated BEAM-101 Sickle Cell Trial Data at ASH 2025

Reuters
·
Nov 03

Fmr Llc Makes a Strategic Move with Beam Therapeutics Stock!

TIPRANKS
·
Oct 30

FMR LLC Reports Disposal of Beam Therapeutics Inc. Common Shares

Reuters
·
Oct 30

Beam Therapeutics’ BEAM-301 Study: A Promising Step in Rare Disease Treatment

TIPRANKS
·
Oct 28

AI Biotech Stocks Shined. Recursion Up 15%; Beam Up 14%; Tempus Up 7%; Novavax Up 6%; Crispr And Ginkgo Up 4%; Hims Up 2%

Tiger Newspress
·
Oct 20

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Disc Medicine (IRON)

TIPRANKS
·
Oct 17

U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity

Reuters
·
Oct 10

Beam Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating: Target Price $41

THOMSON REUTERS
·
Oct 10

Beam Therapeutics initiated with a Buy at Jefferies

TIPRANKS
·
Oct 09

Can Analyst Optimism Around BEAM's Base Editing Progress Reveal Its Edge in Genetic Disease Treatment?

Simply Wall St.
·
Oct 09

Beam Therapeutics Inc : JP Morgan Cuts Target Price to $46 From $48

THOMSON REUTERS
·
Oct 09